Jubilant Pharmova Q1 result: Net profit declines 79% YoY to ₹103 crore; revenue rises 10%

Jubilant Pharmova on Tuesday, July 29, reported a 78.66% year-on-year (YoY) decline in its consolidated net profit to ₹102.9 crore in the first quarter of FY26 (Q1FY26), compared to ₹482.1 crore in the corresponding period a year earlier.

The pharmaceutical company’s revenue from operations, however, surged 9.76% YoY to ₹1,900.7 crore during the quarter under review, as against ₹1,731.7 crore in the June quarter of FY25.

During the quarter, the drug maker earned revenue worth ₹868.6 crore from radiopharma, which grew 4.39% YoY from ₹832.1 crore in the Q1FY25. Its revenue from allergy immunotherapy rose 7.41% YoY to ₹191.4 crore from ₹178.2 crore. Its contract development and manufacturing organisation - sterile injectables segment revenue stood at ₹392.6 crore, up 17.51% YoY from ₹334.1 crore. Furthermore, its contract research, development and manufacturing organisation segment generated ₹311.4 crore in revenue in Q1FY26, jumping 24.91% YoY from ₹249.3 crore. It generated ₹166 crore in revenue from its generics segment, which grew 6.68% YoY from ₹155.6 crore.

While the US market contributed 79% to Jubilant Pharmova’s revenue mix, it generated 21% of its revenue from the rest of the world.

At an operational level, the drug manufacturer’s EBITDA (earnings before interest, tax, depreciation and amortisation) stood at ₹302 crore, up 14% YoY from ₹266 crore in Q1FY25. Its margin expanded by 60 basis points to 15.8%, compared to 15.2% in the same period last fiscal year.

Commenting on the result, Shyam S Bhartia, Chairman and Hari S Bhartia, the Co-Chairman & Non-Executive Director, Jubilant Pharmova, said: "During Q1’FY26, we saw continued growth momentum from Ruby-Fill® and PET radiopharmacies. In the Allergy Immunotherapy, we witnessed an increase in demand from the US. In the CDMO Sterile Injectables, strong customer traction for Line 3 in Spokane continues. In the CRDMO business, we integrated the new R&D facility in France and are now investing in business development initiatives."

"In the Generics business, we are foreseeing growth & profitability improvement. Lastly, in our Proprietary Novel drugs business, we continue to progress in dosing patients in JBI-802 and JBI-778 clinical trials,” they added.

Resignation

In a separate filing, the pharma company informed the exchanges that Arvind Chokhany, its Chief Financial Officer (CFO) and Whole-Time Director (WTD), resigned from Jubilant Pharmover on July 29.

Chokhany cited “external opportunities” as the reason for his resignation, which will be effective on September 30, 2025.

Shares of Jubilant Pharmova closed 1.75% lower at ₹1,153.60 apiece on the National Stock Exchange (NSE) on Tuesday.

The firm has a total market capitalisation of ₹18,374.67 crore, as of July 29, 2025, as per data on the NSE.